ArticleScientific reports2024
Computational design of potent dimeric phenylthiazole NS5A inhibitors for hepatitis C virus.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) presents a significant global health issue due to its widespread prevalence and the absence of a reliable vaccine for prevention. While significant progress has been achieved in therapeutic interventions since the disease was first identified, its resurgence underscores the need for innovative strategies to combat it. The nonstructural protein NS5A is crucial in the life cycle of the HCV, serving as a significant factor in both viral replication and assembly processes. This significance is highlighted by its inclusion in all existing approved HCV combination therapies. In this study, a quantitative structure-activity relationship (QSAR) was conducted to design new compounds with enhanced inhibitory activity against HCV. In this context, a set of 82 phenylthiazole derivatives was employed to construct a QSAR model using the Monte Carlo optimization technique. This model offers valuable insights into the specific structural characteristics that either enhance or reduce the inhibitory activity. These findings were used to design novel NS5A inhibitors. Moreover, molecular docking was used to predict the binding affinity of the newly designed inhibitors within the NS5A protein, followed by molecular dynamics simulations to investigate the dynamic interactions over time. Additionally, molecular mechanics generalized born surface area calculations were carried out to estimate the binding free energies of the inhibitor candidates, providing additional insights into their binding affinities and stabilities. Finally, the absorption, distribution, metabolism, excretion, and toxicity analysis were performed to assess the pharmacokinetic and toxicity profiles of the inhibitor candidates. This comprehensive approach provides a detailed understanding of the potential efficacy, stability, and safety of the screened drug candidates, offering valuable insights for their further development as potent therapeutic agents against HCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.